from the UK and France before the country bans unnecessary travel between both countries to contain violent Omicron infections.
French Prime Minister Jean Castex says the Omicron variant will be the dominant strain of coronavirus in France from early 2022, comparing its spread in Europe to “lightning”.
Meanwhile, the World Health Organization on Friday released a list of emergency uses for the anti-COVID vaccine Covovax produced by the Serum Institute of India under license from Novavax, expanding the basket of jabs validated by the Global Health Organization against the viral disease. Adar Poonawalla, Executive Director of the Serum Institute of India (SII), hailed the WHO decision as “another milestone” in the fight against COVID-19.
“The WHO issued an emergency use note for Covovax, which expanded the basket of WHO-validated vaccines against COVID-19. The vaccine is manufactured by the Serum Institute of India under license from Novavax,” the World Health Organization said in a tweet Friday.
Officials told The Times of India that if daily cases in Britain and France are extrapolated in the context of India’s population, they would mean 14-15 lakh cases, stressing that India is facing a stage of “concern” with the onset of Winter. day. “As Omicron is spreading very rapidly across Europe and most parts of the world, there is a need to avoid unnecessary travel and mass gatherings. New Year celebrations need to be subdued,” ICMR Director General Dr. Balram Bhargava told TOI.
So far, in India, the Omicron cases – Maharashtra (32), Delhi (22) and Rajasthan (17) have reported the maximum number of cases, Karnataka and Telangana have registered eight each, Gujarat and Kerala five each, and Andhra Pradesh, Chandigarh, Tamil Nadu and West Bengal each until 16.00 Friday.